NCT06043193Recruiting
Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.
Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study consists of having participants complete quality of life questionnaires (PROMs) at the time of the cures +/- one week and in the middle of the intercure time +/- one week. As all the collection times do not correspond to a consultation or a visit to a medical service, The investigator wanted to develop a remote, computerized data collection solution. Researchers have programmed an AURA-RIV-TNE care pathway (MOCAs: Engine for the organization and coordination of health acts) on the myHCL patient environment, taking up the course of the study presented in the form of a table in paragraph 6.2. Once the patient consents to participate in the study, he must create an account on the patient interface of his investigation center (myHCL, myCHUGA etc) as much as possible to facilitate data extraction. Once the patient consents to participate in the study, the MOCAs AURA-RIV-TNE course will be associated with him in the Easily software, by defining the date week 0 (baseline) of the first treatment. This will allow automated sending of MAIL and SMS reminders at each questionnaire time. The MAILs will contain an internet link allowing the participant to be directly written to the questionnaires to be completed. A reminder system will be possible if the patient does not complete the questionnaire.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 10 Aug 2023
- Start date
- Feb 2024
- Primary completion date
- Mar 2025
- Lead sponsor
- Hospices Civils de Lyon
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06043193
What you commit to
- Study type: Observational
- Planned participants: 100
- From Feb 2024 to the primary completion date, Mar 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Persons deprived of their liberty by a judicial or administrative decision;
- Adults subject to a legal protection measure (guardianship, curatorship);
Who the study is looking for
- Age \>18 years;
- Patient starting treatment with RIV validated in the RENATEN RCP;
- Patient having received written information about the study;
- Collection of the patient's non-objection
- Patients for whom treatment with RIV is administered within the framework of a clinical trial, may be included in the AURARIV-TNE study according to the written indications written in the 2 nd protocol of the sponsor of the clinical trial;
- Patients undergoing re-treatment with RIV can be included;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CH Métropole-Savoie Coordinator of this site? Confirm its status | Chambéry | France | Recruiting |
| Centre de lutte contre le cancer Jean Perrin Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
| Hospices Civils de Lyon (Hôpital Lyon Sud) Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| CHU de Saint-Etienne - Hôpital nord Coordinator of this site? Confirm its status | Saint-Priest-en-Jarez | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.